Ex vivo and in vitro effect of human immunodeficiency virus protease inhibitors on neutrophil apoptosis.

Polymorphonuclear leukocytes (PMNL) from human immunodeficiency virus (HIV)-infected patients exhibit accelerated apoptosis and impaired functional activity. HIV protease inhibitor-based therapy produces improvements in both acquired and innate immune responses. Ex vivo and in vitro effects of HIV protease inhibitors on apoptosis and chemotaxis of PMNL were evaluated. After therapy, there was a rapid and significant decrease of PMNL apoptosis, which correlated with increased chemotactic function. These findings were found both in patients with immunological and virological response and in control subjects who showed an increase in CD4(+) T cell counts but no concomitant decline in HIV load. After in vitro treatment with ritonavir or indinavir, apoptosis of both HIV-infected and -uninfected PMNL markedly decreased and correlated with significant enhancement of chemotaxis. These results suggest that HIV protease inhibitors may improve the PMNL function by reducing the apoptosis rate and that this effect may, at least in part, be independent of their antiviral activity.

[1]  J M Andrieu,et al.  HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression-independent mechanism. , 2000, Blood.

[2]  E. Acosta,et al.  Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  A. Badley,et al.  Decreased HIV-associated T cell apoptosis by HIV protease inhibitors. , 2000, AIDS research and human retroviruses.

[4]  R. Grant,et al.  Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. , 2000, The Journal of infectious diseases.

[5]  F. Chiarotti,et al.  Clinical and immunologic response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  Pugliese,et al.  Highly active anti‐retroviral therapy (HAART) is associated with a lower level of CD4+ T cell apoptosis in HIV‐infected patients , 1999, Clinical and experimental immunology.

[7]  M. Reitz,et al.  HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells. , 1999, Journal of human virology.

[8]  N. Young,et al.  Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo. , 1999, Blood.

[9]  A. Khwaja,et al.  Caspase-mediated proteolysis and activation of protein kinase Cdelta plays a central role in neutrophil apoptosis. , 1999, Blood.

[10]  G. d’Ettorre,et al.  Improvement in neutrophil and monocyte function during highly active antiretroviral treatment of HIV-1-infected patients. , 1999, AIDS.

[11]  K. Mullane,et al.  Reversal of accelerated neutrophil apoptosis and restoration of respiratory burst activity with r-metHuG-CSF (Filgrastim therapy in patients with AIDS. , 1999, AIDS.

[12]  V. Calvez,et al.  Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease , 1998, The Lancet.

[13]  I. Schedel,et al.  Highly active antiretroviral therapy , 1998, The Lancet.

[14]  G. Pantaleo.  Immunology of HIV infection. , 1997, Research in immunology.

[15]  K. Mullane,et al.  Accelerated neutrophil apoptosis in the acquired immunodeficiency syndrome. , 1996, The Journal of clinical investigation.

[16]  S. Ben‐Sasson,et al.  Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation , 1992, The Journal of cell biology.

[17]  L. Boxer,et al.  Polymorphonuclear leukocyte function. , 1985, Hospital practice.

[18]  H. Hill,et al.  Polymorphonuclear Leukocyte Function in HIV , 1996 .